Rehabilitation and palliation of patients with bronchial cancer

Part of the Collection de L’Académie Européenne de Médecine de Réadaptation book series (LACADEMIE)


The aims of after-care in the follow-up are to lengthen survival time and to improve quality of life as well (fig. 1.1). Recurrence prevention, early detection of recurrences and therapy of disease recurrence (potentially curative follow-up measures) serve to lengthen survival time (fig. 1.3). Supportive, rehabilitative and palliative measures serve to improve quality of life and activities of daily living (fig. 1.2).


Lung Cancer Chronic Obstructive Pulmonary Disease Brain Metastasis Lung Cancer Patient Radiation Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. — AARC Clinical Practice Guideline (2002) Pulmonary rehabilitation. Respir Care 47(5): 617–25Google Scholar
  2. — Abid SH, Malhotra V, Perry MC (2001) Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 13: 242–8PubMedCrossRefGoogle Scholar
  3. — Abrahm J (2004) Assessment and treatment of patients with malignant spinal cord compression. J Support Oncol 2: 377–401PubMedGoogle Scholar
  4. — Algar FJ, Alvarez A, alvatierra A et al. (2002) Predicting pulmonary complications after pneumonectomy for lung cancer. Eur J Cardiothorac Surg 2003; 23: 201–8CrossRefGoogle Scholar
  5. — Ampil F, Caldito G (2006) Radiotherapy for palliation of lung cancer in patients with compromised hearts. J Pall Med 9,2: 241–2CrossRefGoogle Scholar
  6. — Akira M, Ishikawa H, Yamamoto S (2002) Drug-induced Pneumonitis: Thin-Section CT Findings in 60 Patients Radiology 224: 852–60PubMedCrossRefGoogle Scholar
  7. — Arbeiter K, Prakash U, Tazelaar H et al. (1999) Radiation-Induced Pneumonitis in the “Non-Irradiated” Lung. Mayo Clin Proc. 74: 27–36CrossRefGoogle Scholar
  8. — Aspinal F, Hughes R, Higginson I et al. (2002) A user’s guide to the palliative care outcome scale. Palliative care & policy publications. Kings College, LondonGoogle Scholar
  9. — Barat M, Franchignoni F (2004) Assessment in physical medicine and rehabilitation. Maugeri Foundation Books, PI-ME Press PaviaGoogle Scholar
  10. — Bausewein C, Fegg M, Radbruch L et al. (2005) Validation and clinical application of the German version of the palliative care outcome. J Pain Symptom Manage 30: 51–62PubMedCrossRefGoogle Scholar
  11. — Bergman B, Aaronson N et al. (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire for use in lung cancer clinical trials. Eur J Cancer 30A, 635–42PubMedCrossRefGoogle Scholar
  12. — Bruera E, Ripamonti C (1998) Dyspnea in Patients with Advanced Cancer in Supportive Oncology. Berger A, Portenoy R, Weissman D, ed., Lippincott-Raven, 295–308Google Scholar
  13. — Bundesarbeitsgemeinschaft für Rehabilitation (2003) Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation. Bundesarbeitsgemeinschaft für Rehabilitation FrankfurtGoogle Scholar
  14. — Bunn PA, Lilenbaum R (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 5,95: 341–3Google Scholar
  15. — Cella D, Bonomi A et al. (1995) Reliability and validity of the functional assessment of cancer therapy-lung (Fact-L) quality of life instrument. Lung Cancer 12,3: 199–220PubMedCrossRefGoogle Scholar
  16. — Cella D (1997) The functional assessment of cancer therapy anaemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(suppl 2): 13–9PubMedGoogle Scholar
  17. — Celli BR (2004) Chronic respiratory failure after lung resection: the role of pulmonary rehabilitation. Thorac Surg Clin 14,3: 417–28PubMedCrossRefGoogle Scholar
  18. — Chanan A, Srinivasan S, Czuczman M (2004) Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2: 251–66Google Scholar
  19. — Colchen A, Gonin F, Bonnette P (2004) The place of interventional endoscopy in the treatment of lung cancer. Rev Pneumol Clin 60,3: 48–50CrossRefGoogle Scholar
  20. — Covey, A (2005) Management of malignant pleural effusions and ascites. J Support Oncol 3:169–76PubMedGoogle Scholar
  21. — Delbrück H, Schmid L, Bartsch H et al. (2000) Zur Ergebnisqualität in der onkologischen Rehabilitation. Rehabilitation 39: 359–62PubMedCrossRefGoogle Scholar
  22. — De Gregorio Ariza MA, Gamboa P, Gimeno M et al. (2003) Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol 8: 252–63Google Scholar
  23. — Deschamps, Bernard A, Nichols C et al. (2001) Empyema and brochopleural fistula after pneumonectomy: Factors affecting incidence. Ann. Thorac Surg 72: 243–8PubMedCrossRefGoogle Scholar
  24. — Donner CF (2006) Vocational rehabilitation and pulmonary programs. In: Gobelet C, Franchignoni F (Edit) Vocational rehabilitation Springer Paris 185–194CrossRefGoogle Scholar
  25. — Dorman U, Weis J, Bartsch HH (2006) Qualitätssicherung in der onkologischen Rehabilitation. Der Onkologe, Heidelberg (in Press)Google Scholar
  26. — Dubey S, Brown R, Esmond S et al. (2005) Patient preferences in choosing chemotherapy regiments for advanced non-small cell lung cancer. J Support Oncol 3: 149–54PubMedGoogle Scholar
  27. — Dubois A, Schlaich M et al. (1999) Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care cancer 7: 354CrossRefGoogle Scholar
  28. — Dunton JC (2002) Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7: 11–9PubMedCrossRefGoogle Scholar
  29. — Earle C, Tsai JS, Gelber RD (2001) Effectiveness of chemotherapy for advanced lung cancer in the elderly. J Clin Oncol 19,4: 1064–70PubMedGoogle Scholar
  30. — Edel H, Knauth K (1999) Grundzüge der Atemtherapie Urban & Fischer, MünchenGoogle Scholar
  31. — ESMO (2001) Minimum clinical recommendations for diagnosis, treatment and follow-up of small-cell cancer. Ann Oncol 12: 1051CrossRefGoogle Scholar
  32. — ESMO (2001) Minimum clinical recommendations for diagnosis, treatment and follow-up of non small cell cancer. Ann Oncol 12: 1049CrossRefGoogle Scholar
  33. — Estfan B, LeGrand S (2004) Management of cough in advanced cancer. J Support Oncol 2: 523–7PubMedGoogle Scholar
  34. — Freitag L (2004) Interventional endoscopic treatment. Lung Cancer 45,2: 235–8CrossRefGoogle Scholar
  35. — Fromme E, Eilers KM, Mori M et al. (2004) How accurate is clinician reporting of chemotherapy adverse effects? J Clin Oncol 22,17: 3485–90PubMedCrossRefGoogle Scholar
  36. — Fryback D, Craig BM (2004) Measuring economic outcomes of cancer. J Natl Cancer Inst Monographs 33: 134–41PubMedCrossRefGoogle Scholar
  37. — Gridelli C, Perrone F, Nelli F et al. (2001) Quality of life in lung cancer patients. Annals of oncology 12,3: 21CrossRefGoogle Scholar
  38. — Harada H, Okada M, Sakamoto T et al. (2005) Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg 80,6: 2041–5PubMedCrossRefGoogle Scholar
  39. — Hill K, Amir Z et al. (2003) Do newly diagnosed lung cancer patients feel their concerns are being met? Eur J Cancer Care 12,1: 35–45CrossRefGoogle Scholar
  40. — Hollen P, Grall R et al. (1993) Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer symptom Scale (LCSS). Eur J Cancer 29A,1: 551–8Google Scholar
  41. — Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: Prevalence and risk factors derived from quality of life data. J clin Oncol 18,4: 893–903PubMedGoogle Scholar
  42. — Huisman C, Smit EF, Giaccone G et al. (2000) Second—line chemotherapy in relapsing or refractory non-small cell lung cancer: A review. J Clin Oncol 18: 3722–30PubMedGoogle Scholar
  43. — Kelly K, Bunn J (1998) Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small-cell lung cancer? Lung cancer 20: 85–91PubMedCrossRefGoogle Scholar
  44. — Korfee S, Gauler T, Hepp R et al. (2004) New targeted treatments in lung cancer — overview of clinical trials. Lung Cancer 45,2: 199–208CrossRefGoogle Scholar
  45. — Licker M, Spiliopoulos A, Frey J et al. (2005) Risk factors for early mortality and major complications following pneumonectomy for non small cell carcinoma of the lung. Chest 121: 1890–7CrossRefGoogle Scholar
  46. — Limper AH (2004) Chemotherapy-induced lung disease. Clin Chest Med 25: 53–64PubMedCrossRefGoogle Scholar
  47. — Maguire P, Pitceathly C (2002) Key communication skills and how to aquire them. BMJ 325: 697–700PubMedCrossRefGoogle Scholar
  48. — Maini C, Sciutu R, Romano L, Bergomi S (2003) Radionuclide therapy with bone seeking radionuclides in palliation of painful metastases. J Exp Clin Cancer Res 22,4: 71–4PubMedGoogle Scholar
  49. — Mamon H, Wen PY, Loeffler JS (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation. Epilepsia 40(3): 341–4PubMedCrossRefGoogle Scholar
  50. — Mancuso A, Migliorino M, de Santis S et al. (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of oncoloy 17: 146–150CrossRefGoogle Scholar
  51. — Miller AB et al. (2004) Fruits and vegetables and lung cancer: Findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 108: 269–76PubMedCrossRefGoogle Scholar
  52. — Montazeri A, Gillis CR, McEwen J (1998) Quality of life in patients with lung cancer. Chest 113: 467–81PubMedCrossRefGoogle Scholar
  53. — Muscarotili M, Bossola M, Aversa Z et al. (2006) Prevention and treatment of cancer cachexia: New insights into an old problem. Eurp J Cancer 42: 31–41CrossRefGoogle Scholar
  54. — Mutee F, Jatoi A (2006) Megestrol aceatate for the palliation of anorexia in advanced, incurable patients. Clin Nutr 6Google Scholar
  55. — Neuberger JS, Field RW (2003) Occupation and lung cancer in non smokers. Rev Environ Health 18,4: 251–67PubMedGoogle Scholar
  56. — Paice J (2003) Mechanisms and management of neuropathic pain in cancer. J support Oncol 1,2: 107–14PubMedGoogle Scholar
  57. — Pawel J, Schiller JH, Shepherd FA et al. (1999) Topotecan versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. J Clin Oncol 17,2: 658Google Scholar
  58. — Pezner RD, Bertrand M, Cecchi G et al. (1984) Steroid-withdrawal radiation pneumonitis in cancer patients. Chest 85: 816–7PubMedCrossRefGoogle Scholar
  59. — Ramsey SD, Howlader N, Etzioni RD et al. (2004) Chemotherapy use, outcomes, and costs for older persons with advanced non-small lung cancer. J Clin Oncol 22(24): 4971–8PubMedCrossRefGoogle Scholar
  60. — Rizzo JD, Lichtin A et al. (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of haematology. J Clin Oncol 20: 4083–4107PubMedCrossRefGoogle Scholar
  61. — Robnett T, Machtay M, Vines EF et al. (2000) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Bio Phys 1,48, 1: 89–94CrossRefGoogle Scholar
  62. — Ron IG, Stav O, Vishne T et al. (2004) The correlation between palliation of bone pain by intravenous strontium 89 and external beam radiation to linked field in patients with osteoblastic bone metastases. Am J Clin Oncol 27(5): 5004CrossRefGoogle Scholar
  63. — Rosen LS, Gordon D, Tchekmedyian NS et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung cancer and other solid tumours. Cancer 100,12: 2613–21PubMedCrossRefGoogle Scholar
  64. — Schofield P, Ball D, Smith JG et al. (2004) Optimism and survival in lung carcinoma patients. Cancer 100,6: 1276–82PubMedCrossRefGoogle Scholar
  65. — Seegenschmidt M (1998) Nebenwirkungen in der Onkologie. Springer, Berlin, Heidelberg, New York, TokyoGoogle Scholar
  66. — Seute T, Leffers P, ten Velde GP et al. (2004) Neurologic disorders in 432 consecutive patients with small-cell lung carcinoma. Cancer 100: 801–6PubMedCrossRefGoogle Scholar
  67. — Shepherd F, Pereira J, Ciuleanu T et al. (2005) Erlotinib in previously treated Non-small-cell lung cancer. N Engl J Med 353: 123–32PubMedCrossRefGoogle Scholar
  68. — Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120,2: 617–24PubMedCrossRefGoogle Scholar
  69. — Spruit MA, Janssen PP, Willemsen SC et al. (2006) Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients. Lung Cancer (Mar)Google Scholar
  70. — Stanley H, Kelley K (2004) CNS home visits following diagnosis of lung cancer. Cancer Nursing Practice 3,2: 33–9Google Scholar
  71. — Stinnett H, S, Williams C, Johnson D (2007) Role of chemotherapy for palliation in the lung cancer patient. J Support Oncol 5,1: 19–24PubMedGoogle Scholar
  72. — Sugimura, Yang H (2006) Long-term Survivorship in Lung Cancer*Chest. 129: 1088–97PubMedCrossRefGoogle Scholar
  73. — Tamburini M. (2001) Health related quality of life measures in cancer. Ann Oncol 12(suppl 3): 7CrossRefGoogle Scholar
  74. — Thomas J, von Gunten C (2003) Management of dyspnea. J Support Oncol 1: 23–32PubMedGoogle Scholar
  75. — Von Pawel J, Gatzemeier U, Pujol JL et al. (2001) Comparator of oral versus intravenous Topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19: 1743–9Google Scholar
  76. — Wells M, Sarna L, Cooley M et al. (2007) Use of complementary and alternative medicine therapies to control symptoms in women living with lung cancer. Cancer Nurs 30,1: 45–55PubMedCrossRefGoogle Scholar
  77. — Zatloukal P, Petrzelka L et al. (2004) Concurrent versus sequential chemo radiotherapy with cisplatin and vinorelbine in locally advanced non-small-cell lung cancer: A randomized study. Lung cancer 46,1: 87–98PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2007

Personalised recommendations